Find Garsorasib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Garsorasib [inn], 2559761-14-5, P491ne9g6z, Unii-p491ne9g6z, 4-((2s,5r)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-6-fluoropyrido(2,3-d)pyrimidin-2(1h)-one, D-1553
Molecular Formula
C32H32F2N8O2
Molecular Weight
598.6  g/mol
InChI Key
DKFRWZJCNPETGI-SJORKVTESA-N
FDA UNII
P491NE9G6Z

Garsorasib
Garsorasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, garsorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
1 2D Structure

Garsorasib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one
2.1.2 InChI
InChI=1S/C32H32F2N8O2/c1-4-24(43)40-13-17(3)41(14-16(40)2)30-20-12-22(34)28(25-21(33)6-5-7-23(25)35)38-31(20)42(32(44)39-30)29-26(18-8-9-18)36-15-37-27(29)19-10-11-19/h4-7,12,15-19H,1,8-11,13-14,35H2,2-3H3/t16-,17+/m1/s1
2.1.3 InChI Key
DKFRWZJCNPETGI-SJORKVTESA-N
2.1.4 Canonical SMILES
CC1CN(C(CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)N)C5=C(N=CN=C5C6CC6)C7CC7
2.1.5 Isomeric SMILES
C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)N)C5=C(N=CN=C5C6CC6)C7CC7
2.2 Other Identifiers
2.2.1 UNII
P491NE9G6Z
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Garsorasib [inn]

2. 2559761-14-5

3. P491ne9g6z

4. Unii-p491ne9g6z

5. 4-((2s,5r)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-6-fluoropyrido(2,3-d)pyrimidin-2(1h)-one

6. D-1553

7. Pyrido(2,3-d)pyrimidin-2(1h)-one, 7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropyl-5-pyrimidinyl)-4-((2s,5r)-2,5-dimethyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-6-fluoro-

8. Garsorasib [who-dd]

9. Chembl5095066

10. Schembl22704797

11. Glxc-26938

12. Ex-a5695

13. Akos040757847

14. Ms-30601

15. Hy-145571

16. Cs-0376098

17. D 1553

18. 7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2s,5r)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one

2.4 Create Date
2021-01-23
3 Chemical and Physical Properties
Molecular Weight 598.6 g/mol
Molecular Formula C32H32F2N8O2
XLogP33.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count6
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area121
Heavy Atom Count44
Formal Charge0
Complexity1150
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 2559761-14-5 / Garsorasib API manufacturers, exporters & distributors?

Garsorasib manufacturers, exporters & distributors 1

11

PharmaCompass offers a list of Garsorasib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Garsorasib manufacturer or Garsorasib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Garsorasib manufacturer or Garsorasib supplier.

PharmaCompass also assists you with knowing the Garsorasib API Price utilized in the formulation of products. Garsorasib API Price is not always fixed or binding as the Garsorasib Price is obtained through a variety of data sources. The Garsorasib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Garsorasib

Synonyms

Garsorasib [inn], 2559761-14-5, P491ne9g6z, Unii-p491ne9g6z, 4-((2s,5r)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-6-fluoropyrido(2,3-d)pyrimidin-2(1h)-one, D-1553

Cas Number

2559761-14-5

Unique Ingredient Identifier (UNII)

P491NE9G6Z

About Garsorasib

Garsorasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, garsorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

CS-0376098 Manufacturers

A CS-0376098 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CS-0376098, including repackagers and relabelers. The FDA regulates CS-0376098 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CS-0376098 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

CS-0376098 Suppliers

A CS-0376098 supplier is an individual or a company that provides CS-0376098 active pharmaceutical ingredient (API) or CS-0376098 finished formulations upon request. The CS-0376098 suppliers may include CS-0376098 API manufacturers, exporters, distributors and traders.

CS-0376098 GMP

CS-0376098 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of CS-0376098 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CS-0376098 GMP manufacturer or CS-0376098 GMP API supplier for your needs.

CS-0376098 CoA

A CS-0376098 CoA (Certificate of Analysis) is a formal document that attests to CS-0376098's compliance with CS-0376098 specifications and serves as a tool for batch-level quality control.

CS-0376098 CoA mostly includes findings from lab analyses of a specific batch. For each CS-0376098 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

CS-0376098 may be tested according to a variety of international standards, such as European Pharmacopoeia (CS-0376098 EP), CS-0376098 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CS-0376098 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty